337 related articles for article (PubMed ID: 28704384)
81. Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: a retrospective cohort study.
Patell R; Mikhael A; Tabet M; Bena J; Berber E; Nasr C
Endocrine; 2018 Sep; 61(3):506-510. PubMed ID: 29948933
[TBL] [Abstract][Full Text] [Related]
82. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
[TBL] [Abstract][Full Text] [Related]
83. Predicting
Liu M; Cheng L; Jin Y; Ruan M; Sheng S; Chen L
Sci Rep; 2018 Mar; 8(1):4352. PubMed ID: 29531251
[TBL] [Abstract][Full Text] [Related]
84. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.
Nascimento C; Borget I; Troalen F; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Chougnet CN; Baudin E; Schlumberger M; Leboulleux S
Eur J Endocrinol; 2013 Nov; 169(5):689-93. PubMed ID: 23939918
[TBL] [Abstract][Full Text] [Related]
85. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.
Kwon SY; Lee SW; Kong EJ; Kim K; Kim BI; Kim J; Kim H; Park SH; Park J; Park HL; Oh SW; Won KS; Ryu YH; Yoon JK; Lee SJ; Lee JJ; Chong A; Jeong YJ; Jeong JH; Cho YS; Cho A; Cheon GJ; Choi EK; Hwang JP; Bae SK;
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):561-571. PubMed ID: 31820047
[TBL] [Abstract][Full Text] [Related]
86. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
[TBL] [Abstract][Full Text] [Related]
87. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer.
Meng Z; Tan J; Zhang G; Tian W; Fu Q; Li W; He X; Wu S; Yang Z; Liang X; Dong L; Zhang Q; Liu L; Zhang Y; Xu K; Liu B; Li N; Li X; Jia Q; He Y; Wang S; Wang R; Zheng W; Song X; Zhang J; Hu T; Liu N; Upadhyaya A
Life Sci; 2015 Jun; 130():18-24. PubMed ID: 25817231
[TBL] [Abstract][Full Text] [Related]
88. Prognostic Value of Pre-Ablation Stimulated Thyroglobulin in Children and Adolescents with Differentiated Thyroid Cancer.
Liu L; Zhang X; Tian T; Huang R; Liu B
Thyroid; 2020 Jul; 30(7):1017-1024. PubMed ID: 31964278
[No Abstract] [Full Text] [Related]
89. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer.
Bandeira L; Padovani RDP; Ticly AL; Cury AN; Scalissi NM; Marone MMS; Ferraz C
Arch Endocrinol Metab; 2017 Dec; 61(6):590-599. PubMed ID: 29412384
[TBL] [Abstract][Full Text] [Related]
90. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
91. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
92. Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer.
Ledwon A; Paliczka-Cieślik E; Syguła A; Olczyk T; Kropińska A; Kotecka-Blicharz A; Hasse-Lazar K; Kluczewska-Gałka A; Jarząb B; Handkiewicz-Junak D
Ann Nucl Med; 2021 Nov; 35(11):1214-1222. PubMed ID: 34363597
[TBL] [Abstract][Full Text] [Related]
93. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
[TBL] [Abstract][Full Text] [Related]
94. Factors Predicting Early Release of Thyroid Cancer Patients from the Isolation Room after Radioiodine-131 Treatment.
Fatima N; Zaman Mu; Zaman A; Zaman U; Tahseen R; Shahid W
Asian Pac J Cancer Prev; 2016; 17(1):125-9. PubMed ID: 26838196
[TBL] [Abstract][Full Text] [Related]
95. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
[TBL] [Abstract][Full Text] [Related]
96. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival.
Piccardo A; Arecco F; Puntoni M; Foppiani L; Cabria M; Corvisieri S; Arlandini A; Altrinetti V; Bandelloni R; Orlandi F
Clin Nucl Med; 2013 Jan; 38(1):18-24. PubMed ID: 23242039
[TBL] [Abstract][Full Text] [Related]
97. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
[TBL] [Abstract][Full Text] [Related]
98. Response to (131)I Therapy in Non-metastatic Differentiated Thyroid CancerPatients with Preablative Stimulated Thyroglobulin above 10 ng/ml.
Hou M; Zhao T; Yang X; Li J; Li H; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Feb; 38(1):83-7. PubMed ID: 26956862
[TBL] [Abstract][Full Text] [Related]
99. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
[TBL] [Abstract][Full Text] [Related]
100. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.
Li G; Lei J; Song L; Jiang K; Wei T; Li Z; Gong R; Zhu J
Cancer Med; 2018 Nov; 7(11):5448-5456. PubMed ID: 30264548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
